Common use of 88g Clause in Contracts

88g. docosahexanoic acid [DHA] 1.48g) using on pt outcome, but there was wide warriation in the phospholipid (PL) O3/O6 and EPA/arachidonic acid (AA) levels. The purpose of this study was to determine the cause for this variabilityand to evaluate if the PL O3/O6 and EPA/AA levels affected the outcome of the pts. PLFA levels were measured after 21 months in 23 pts who received O3FA taged 7-10 years and weighing 25-25 kg. and in 11 placebo pts. A Clinical Outcome Score (COS) ranging from -10 to +10 was determined for each pt based on the mean values of estimated GFR and urine protein/creatinnie ratios (UP/C) after 18 and 24 months versus baseline. The dosage of O3FA given to each pt was calculated as g/kg BWt and g/m BSA. Adherence to therapy (Adh-Rx) was based on pill counts. Correlations were determined between the variables of interest and expressed as Xxxxxxxx’x rho (rho). Xxx XX X0/X0 ratios ranged from 0.17 to 0.58 (mean 0.34) and the EPA/AA ratios ranged from 0.06 to 0.91 (0.42 ) in the 23 pts. versus 0.06-0.13 and 0.03-0.09 in the placebo pts. There was no relationship between the O3/O6 and EPA/AA ratios and Adh-RX (rho=0.09, rho=0.20. The PL O3/O6 and EPA/AA ratios were closely correlated with BW (rho=0.68 and 0.80 p=0.0001 and g/m(2) rho=0.69 and 0.82 p=0.0001). As expected the PL EPA/AA and DHA/AA were closely correlated rho=0.85 p=0.0001. The COS correlated with O3/O6 rho=0.53 p=0.009 EPA/AA rho=0.50 p=0.0003 dose in g/kg rho=0.55 p=0.006 and dose/m(2) BSA rho=0.54 p=0.008,. but out Adh-RX (rho=0.21). These data suggest that the efficacy of O3FA Rs for JgAN pts is dose-dependent and that therapy with EPA+DHA is of benefit if dosing is done according to body size and/or EPA/AA levels. Branding Guidelines OMACOR® icosapent/doconexent Table of Contents icosapent/doconexent ® Apo B–100 Apo E Apo C VLDL–Triglycerides VLDL remnant LDL Other sites Liver Inhibition of VLDL– Triglyceride synthesis Branding Omacor® Logotype Symbol Colour Environment Logo Cluster Graphic Styling Branding Omacor® In order to build a pharmaceutical brand in today’s crowded and competitive marketplace, it is essential that all materials maintain a strong, distinctive and consistent visual image. Each of the product’s branding components should therefore be used consistently and repeatedly wherever and whenever the product is promoted in its markets around the world. The benefit to individual marketing companies is that strong product branding produces a more distinct and powerful image for a product. In turn, this complements the other elements of the marketing mix, to build a brand that is stronger, more durable, and therefore more successful. These guidelines are provided to help you to build Omacor® as a pharmaceutical brand that will differentiate itself in the current market and continue to be distinctive and relevant as the market evolves. The four key “global branding” components for Omacor® have been developed to endure over time, regardless of changes in advertising “fashions”. They are: Distinctive Logotype (i.e., the typestyle of the brand name) Unique and Relevant Symbol Distinctive Brand Colour Environment Consistent Visual Styling (typefaces, design, photography and artwork) icosapent/doconexent The Omacor® Logotype + Generic name The representation of the brand name, or ‘logotype’, is the most important of all branding elements. Omacor® is produced by a unique process, making it a unique drug, that therefore deserves a unique and distinctive logotype. icosapent/doconexent The consistent use of the generic name together with the logotype is essential to the pharmaceutical image of Omacor®. The generic name for Omacor® is icosapent/doconexent. The logotype should always be used together with the generic name. It is recommended also to use the symbol wherever possible. The symbol to employ when used with the logotype is the boxed form which can be seen throughout this binder in the logo/symbol configuration. A description of the symbol is given in ‘The Omacor Symbol’ section. Use the Omacor logotype with the ® symbol in all countries where the trademark has been registered, and the ™ symbol in all other countries. The Omacor® Symbol The Omacor® symbol has a blood vessel as its inspiration; it also reflects the ‘O’ of Omacor®. The symbol has been rendered with a ‘segmented’ effect, to allude to the multi-factorial nature of the disease area, and to the multi-stage PUFA-XPC purification process. This segmentation effect also allows the central counterspace to be developed into a heart shape. The Omacor® symbol may be used as a graphic device (as can be seen throughout these guidelines), with the following recommendations: In whole or in part, the surrounding box omitted. In this form it should be noted that the segment which passes through the box appears intact and not divided by the box rule. The individual segments may be used graphically or photographically. The symbol should only be used in the boxed form when in the logo/symbol configuration. The boxed form highlights the symbol. This not only separates the symbol from the logotype as a distinct visual element but creates integrity to the logo/ symbol unit by being the same height as the OMACOR lettering. icosapent/doconexent The Omacor® Logo/Symbol When reproducing the Omacor® logotype and symbol together – the logo/symbol – it is essential that the various elements are kept in the correct proportions and relative positions, together with consistent application of branding colours (see Colour Environment). icosapent/doconexent Colour and black and white reproducible art, for both the larger and smaller versions of the logo/symbol, are included at the back of this binder. The Omacor® Colour Environment It is important that, whenever possible, the Omacor® logotype and symbol be reproduced in full colour. Please see the colour keys on this page for information required to reproduce these colours with the Pantone Matching System (PMS) colour system, four-colour process, and with an Apple Macintosh computer. The branding colours selected for Omacor® are: PMS 2587C, PMS 326C, and PMS 293C. When budget considerations require black and white reproduction, please refer to the reproducible art sheets at the back of this binder. PMS 2587C Four-colour process C 72% M 79% Y 0% K 0% Apple Macintosh R 54.1% G 12.5% B 85.9% Hue 76.1% Saturation 85.4% Brightness 85.9%. PMS 326C Four-colour process C 94% M 0% Y 43% K 0% Apple Macintosh R 42.0% G 72.5% B 63.1% Hue 44.9% Saturation 42.2% Brightness 72.5% PMS 293C Four-colour process C 100% M 56% Y 0% K 0% Apple Macintosh R 0% G 0% B 70.6% Hue 66.7% Saturation 100% Brightness 70.6% Please note, the colour reproduction in these prints is not exact. icosapent/doconexent The Omacor® Logo Cluster The Omacor® “logo cluster” is created by the combination of the following elements: Eyebrow Logotype Symbol Generic name Biosynthesised icosapent/doconexent These elements are described and discussed on the following page. The Omacor® logo cluster should be used, whenever possible and wherever appropriate, in promotional and educational materials. Reproducible art sheets for the Omacor® logo cluster are included at the back of this binder. Eyebrow The eyebrow sits above the brand name. It may be reproduced in either black or in reversed-out white type. Generic Name The generic name, icosapent/doconexent, is positioned flush left. The recommended size is indicated but, of course, is subject to national regulatory control. It should appear in black, or in reversed-out white type. Biosynthesised icosapent/doconexent The Omacor® Background The Omacor® background has been developed to further enhance the page layouts, and to emphasise typographic points. This background is a series of horizontal bands orchestrated down a blue vignette. 55% As can be seen throughout these guidelines the Omacor® logo cluster should always remain on a white background. 70% It is possible to create this background. The colour to use is PMS 293C. The percentages of PMS 293C are shown on this page. 55% It is advisable to discuss this background with your local Art Studio. 70% 25% 25% 25% 0% icosapent/doconexent Omacor® Colour Priorities If reproduction considerations, or budgetary constraints, do not allow use of 4-colour reproduction, the colour directions to use are shown below. The PMS colours chosen being those described previously. icosapent/doconexent 3-colour reproduction PMS 2587 PMS 326 PMS 293 icosapent/doconexent 1-colour reproduction PMS 2587 icosapent/doconexent Black and white reproduction icosapent/doconexent For reproduction on a dark background PMS 2587C PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS 326C PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS 293C PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293

88g. docosahexanoic acid [DHA] 1.48g) using on pt outcome, but there was wide warriation in the phospholipid (PL) O3/O6 and EPA/arachidonic acid (AA) levels. The purpose of this study was to determine the cause for this variabilityand to evaluate if the PL O3/O6 and EPA/AA levels affected the outcome of the pts. PLFA levels were measured after 21 months in 23 pts who received O3FA taged 7-10 years and weighing 25-25 kg. and in 11 placebo pts. A Clinical Outcome Score (COS) ranging from -10 to +10 was determined for each pt based on the mean values of estimated GFR and urine protein/creatinnie ratios (UP/C) after 18 and 24 months versus baseline. The dosage of O3FA given to each pt was calculated as g/kg BWt and g/m BSA. Adherence to therapy (Adh-Rx) was based on pill counts. Correlations were determined between the variables of interest and expressed as Xxxxxxxx’x rho (rho). Xxx XX X0/X0 ratios ranged from 0.17 to 0.58 (mean 0.34) and the EPA/AA ratios ranged from 0.06 to 0.91 (0.42 ) in the 23 pts. versus 0.06-0.13 and 0.03-0.09 in the placebo pts. There was no relationship between the O3/O6 and EPA/AA ratios and Adh-RX (rho=0.09, rho=0.20. The PL O3/O6 and EPA/AA ratios were closely correlated with BW (rho=0.68 and 0.80 p=0.0001 and g/m(2) m2 rho=0.69 and 0.82 p=0.0001). As expected the PL EPA/AA and DHA/AA were closely correlated rho=0.85 p=0.0001. The COS correlated with O3/O6 rho=0.53 p=0.009 EPA/AA rho=0.50 p=0.0003 dose in g/kg rho=0.55 p=0.006 and dose/m(2) m2 BSA rho=0.54 p=0.008,. but out Adh-RX (rho=0.21). These data suggest that the efficacy of O3FA Rs for JgAN pts is dose-dependent and that therapy with EPA+DHA is of benefit if dosing is done according to body size and/or EPA/AA levels. Branding Guidelines OMACOR® icosapent/doconexent Table of Contents icosapent/doconexent ® Apo B–100 Apo E Apo C VLDL–Triglycerides VLDL remnant LDL Other sites Liver Inhibition of VLDL– Triglyceride synthesis Branding Omacor® Logotype Symbol Colour Environment Logo Cluster Graphic Styling Branding Omacor® In order to build a pharmaceutical brand in today’s crowded and competitive marketplace, it is essential that all materials maintain a strong, distinctive and consistent visual image. Each of the product’s branding components should therefore be used consistently and repeatedly wherever and whenever the product is promoted in its markets around the world. The benefit to individual marketing companies is that strong product branding produces a more distinct and powerful image for a product. In turn, this complements the other elements of the marketing mix, to build a brand that is stronger, more durable, and therefore more successful. These guidelines are provided to help you to build Omacor® as a pharmaceutical brand that will differentiate itself in the current market and continue to be distinctive and relevant as the market evolves. The four key “global branding” components for Omacor® have been developed to endure over time, regardless of changes in advertising “fashions”. They are[***]: Distinctive Logotype (i.e., the typestyle of the brand name) Unique and Relevant Symbol Distinctive Brand Colour Environment Consistent Visual Styling (typefaces, design, photography and artwork) icosapent/doconexent The Omacor® Logotype + Generic name The representation of the brand name, or ‘logotype’, is the most important of all branding elements. Omacor® is produced by a unique process, making it a unique drug, that therefore deserves a unique and distinctive logotype. icosapent/doconexent The consistent use of the generic name together with the logotype is essential to the pharmaceutical image of Omacor®. The generic name for Omacor® is icosapent/doconexent. The logotype should always be used together with the generic name. It is recommended also to use the symbol wherever possible. The symbol to employ when used with the logotype is the boxed form which can be seen throughout this binder in the logo/symbol configuration. A description of the symbol is given in ‘The Omacor Symbol’ section. Use the Omacor logotype with the ® symbol in all countries where the trademark has been registered, and the ™ symbol in all other countries. The Omacor® Symbol The Omacor® symbol has a blood vessel as its inspiration; it also reflects the ‘O’ of Omacor®. The symbol has been rendered with a ‘segmented’ effect, to allude to the multi-factorial nature of the disease area, and to the multi-stage PUFA-XPC purification process. This segmentation effect also allows the central counterspace to be developed into a heart shape. The Omacor® symbol may be used as a graphic device (as can be seen throughout these guidelines), with the following recommendations: In whole or in part, the surrounding box omitted. In this form it should be noted that the segment which passes through the box appears intact and not divided by the box rule. The individual segments may be used graphically or photographically. The symbol should only be used in the boxed form when in the logo/symbol configuration. The boxed form highlights the symbol. This not only separates the symbol from the logotype as a distinct visual element but creates integrity to the logo/ symbol unit by being the same height as the OMACOR lettering. icosapent/doconexent The Omacor® Logo/Symbol When reproducing the Omacor® logotype and symbol together – the logo/symbol – it is essential that the various elements are kept in the correct proportions and relative positions, together with consistent application of branding colours (see Colour Environment). icosapent/doconexent Colour and black and white reproducible art, for both the larger and smaller versions of the logo/symbol, are included at the back of this binder. The Omacor® Colour Environment It is important that, whenever possible, the Omacor® logotype and symbol be reproduced in full colour. Please see the colour keys Certain information on this page for information required to reproduce these colours has been omitted and filed separately with the Pantone Matching System (PMS) colour system, four-colour process, and Commission. Confidential treatment has been requested with an Apple Macintosh computer. The branding colours selected for Omacor® are: PMS 2587C, PMS 326C, and PMS 293C. When budget considerations require black and white reproduction, please refer respect to the reproducible art sheets at the back of omitted portions. [***]: Certain information on this binder. PMS 2587C Four-colour process C 72% M 79% Y 0% K 0% Apple Macintosh R 54.1% G 12.5% B 85.9% Hue 76.1% Saturation 85.4% Brightness 85.9%. PMS 326C Four-colour process C 94% M 0% Y 43% K 0% Apple Macintosh R 42.0% G 72.5% B 63.1% Hue 44.9% Saturation 42.2% Brightness 72.5% PMS 293C Four-colour process C 100% M 56% Y 0% K 0% Apple Macintosh R 0% G 0% B 70.6% Hue 66.7% Saturation 100% Brightness 70.6% Please note, the colour reproduction in these prints is not exact. icosapent/doconexent The Omacor® Logo Cluster The Omacor® “logo cluster” is created by the combination of the following elements: Eyebrow Logotype Symbol Generic name Biosynthesised icosapent/doconexent These elements are described and discussed on the following page. The Omacor® logo cluster should be used, whenever possible and wherever appropriate, in promotional and educational materials. Reproducible art sheets for the Omacor® logo cluster are included at the back of this binder. Eyebrow The eyebrow sits above the brand name. It may be reproduced in either black or in reversed-out white type. Generic Name The generic name, icosapent/doconexent, is positioned flush left. The recommended size is indicated but, of course, is subject to national regulatory control. It should appear in black, or in reversed-out white type. Biosynthesised icosapent/doconexent The Omacor® Background The Omacor® background page has been developed omitted and filed separately with the Commission. Confidential treatment has been requested with respect to further enhance the page layouts, and to emphasise typographic points. This background is a series of horizontal bands orchestrated down a blue vignette. 55% As can be seen throughout these guidelines the Omacor® logo cluster should always remain on a white background. 70% It is possible to create this background. The colour to use is PMS 293C. The percentages of PMS 293C are shown on this page. 55% It is advisable to discuss this background with your local Art Studio. 70% 25% 25% 25% 0% icosapent/doconexent Omacor® Colour Priorities If reproduction considerations, or budgetary constraints, do not allow use of 4-colour reproduction, the colour directions to use are shown below. The PMS colours chosen being those described previously. icosapent/doconexent 3-colour reproduction PMS 2587 PMS 326 PMS 293 icosapent/doconexent 1-colour reproduction PMS 2587 icosapent/doconexent Black and white reproduction icosapent/doconexent For reproduction on a dark background PMS 2587C PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS 326C PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS 293C PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293omitted portions.

88g. docosahexanoic acid [DHA] 1.48g) using on pt outcome, but there was wide warriation in the phospholipid (PL) O3/O6 and EPA/arachidonic acid (AA) levels. The purpose of this study was to determine the cause for this variabilityand to evaluate if the PL O3/O6 and EPA/AA levels affected the outcome of the pts. PLFA levels were measured after 21 months in 23 pts who received O3FA taged 7-10 years and weighing 25-25 kg. and in 11 placebo pts. A Clinical Outcome Score (COS) ranging from -10 to +10 was determined for each pt based on the mean values of estimated GFR and urine protein/creatinnie ratios (UP/C) after 18 and 24 months versus baseline. The dosage of O3FA given to each pt was calculated as g/kg BWt and g/m BSA. Adherence to therapy (Adh-Rx) was based on pill counts. Correlations were determined between the variables of interest and expressed as Xxxxxxxx’x rho (rho). Xxx XX X0/X0 ratios ranged from 0.17 to 0.58 (mean 0.34) and the EPA/AA ratios ranged from 0.06 to 0.91 (0.42 ) in the 23 pts. versus 0.06-0.13 and 0.03-0.09 in the placebo pts. There was no relationship between the O3/O6 and EPA/AA ratios and Adh-RX (rho=0.09, rho=0.20. The PL O3/O6 and EPA/AA ratios were closely correlated with BW (rho=0.68 and 0.80 p=0.0001 and g/m(2) rho=0.69 and 0.82 p=0.0001). As expected the PL EPA/AA and DHA/AA were closely correlated rho=0.85 p=0.0001. The COS correlated with O3/O6 rho=0.53 p=0.009 EPA/AA rho=0.50 p=0.0003 dose in g/kg rho=0.55 p=0.006 and dose/m(2) BSA rho=0.54 p=0.008,. but out Adh-RX (rho=0.21). These data suggest that the efficacy of O3FA Rs for JgAN pts is dose-dependent and that therapy with EPA+DHA is of benefit if dosing is done according to body size and/or EPA/AA levels. Branding Guidelines OMACOR® icosapent/doconexent Table of Contents icosapent/doconexent ® Apo B–100 Apo E Apo C VLDL–Triglycerides VLDL remnant LDL Other sites Liver Inhibition of VLDL– Triglyceride synthesis Branding Omacor® Logotype Symbol Colour Environment Logo Cluster Graphic Styling Branding Omacor® In order to build a pharmaceutical brand in today’s crowded and competitive marketplace, it is essential that all materials maintain a strong, distinctive and consistent visual image. Each of the product’s branding components should therefore be used consistently and repeatedly wherever and whenever the product is promoted in its markets around the world. The benefit to individual marketing companies is that strong product branding produces a more distinct and powerful image for a product. In turn, this complements the other elements of the marketing mix, to build a brand that is stronger, more durable, and therefore more successful. These guidelines are provided to help you to build Omacor® as a pharmaceutical brand that will differentiate itself in the current market and continue to be distinctive and relevant as the market evolves. The four key “global branding” components for Omacor® have been developed to endure over time, regardless of changes in advertising “fashions”. They are[***]: Distinctive Logotype (i.e., the typestyle of the brand name) Unique and Relevant Symbol Distinctive Brand Colour Environment Consistent Visual Styling (typefaces, design, photography and artwork) icosapent/doconexent The Omacor® Logotype + Generic name The representation of the brand name, or ‘logotype’, is the most important of all branding elements. Omacor® is produced by a unique process, making it a unique drug, that therefore deserves a unique and distinctive logotype. icosapent/doconexent The consistent use of the generic name together with the logotype is essential to the pharmaceutical image of Omacor®. The generic name for Omacor® is icosapent/doconexent. The logotype should always be used together with the generic name. It is recommended also to use the symbol wherever possible. The symbol to employ when used with the logotype is the boxed form which can be seen throughout this binder in the logo/symbol configuration. A description of the symbol is given in ‘The Omacor Symbol’ section. Use the Omacor logotype with the ® symbol in all countries where the trademark has been registered, and the ™ symbol in all other countries. The Omacor® Symbol The Omacor® symbol has a blood vessel as its inspiration; it also reflects the ‘O’ of Omacor®. The symbol has been rendered with a ‘segmented’ effect, to allude to the multi-factorial nature of the disease area, and to the multi-stage PUFA-XPC purification process. This segmentation effect also allows the central counterspace to be developed into a heart shape. The Omacor® symbol may be used as a graphic device (as can be seen throughout these guidelines), with the following recommendations: In whole or in part, the surrounding box omitted. In this form it should be noted that the segment which passes through the box appears intact and not divided by the box rule. The individual segments may be used graphically or photographically. The symbol should only be used in the boxed form when in the logo/symbol configuration. The boxed form highlights the symbol. This not only separates the symbol from the logotype as a distinct visual element but creates integrity to the logo/ symbol unit by being the same height as the OMACOR lettering. icosapent/doconexent The Omacor® Logo/Symbol When reproducing the Omacor® logotype and symbol together – the logo/symbol – it is essential that the various elements are kept in the correct proportions and relative positions, together with consistent application of branding colours (see Colour Environment). icosapent/doconexent Colour and black and white reproducible art, for both the larger and smaller versions of the logo/symbol, are included at the back of this binder. The Omacor® Colour Environment It is important that, whenever possible, the Omacor® logotype and symbol be reproduced in full colour. Please see the colour keys Certain information on this page for information required to reproduce these colours has been omitted and filed separately with the Pantone Matching System (PMS) colour system, four-colour process, and Commission. Confidential treatment has been requested with an Apple Macintosh computer. The branding colours selected for Omacor® are: PMS 2587C, PMS 326C, and PMS 293C. When budget considerations require black and white reproduction, please refer respect to the reproducible art sheets at the back of omitted portions. [***]: Certain information on this binder. PMS 2587C Four-colour process C 72% M 79% Y 0% K 0% Apple Macintosh R 54.1% G 12.5% B 85.9% Hue 76.1% Saturation 85.4% Brightness 85.9%. PMS 326C Four-colour process C 94% M 0% Y 43% K 0% Apple Macintosh R 42.0% G 72.5% B 63.1% Hue 44.9% Saturation 42.2% Brightness 72.5% PMS 293C Four-colour process C 100% M 56% Y 0% K 0% Apple Macintosh R 0% G 0% B 70.6% Hue 66.7% Saturation 100% Brightness 70.6% Please note, the colour reproduction in these prints is not exact. icosapent/doconexent The Omacor® Logo Cluster The Omacor® “logo cluster” is created by the combination of the following elements: Eyebrow Logotype Symbol Generic name Biosynthesised icosapent/doconexent These elements are described and discussed on the following page. The Omacor® logo cluster should be used, whenever possible and wherever appropriate, in promotional and educational materials. Reproducible art sheets for the Omacor® logo cluster are included at the back of this binder. Eyebrow The eyebrow sits above the brand name. It may be reproduced in either black or in reversed-out white type. Generic Name The generic name, icosapent/doconexent, is positioned flush left. The recommended size is indicated but, of course, is subject to national regulatory control. It should appear in black, or in reversed-out white type. Biosynthesised icosapent/doconexent The Omacor® Background The Omacor® background page has been developed omitted and filed separately with the Commission. Confidential treatment has been requested with respect to further enhance the page layouts, and to emphasise typographic points. This background is a series of horizontal bands orchestrated down a blue vignette. 55% As can be seen throughout these guidelines the Omacor® logo cluster should always remain on a white background. 70% It is possible to create this background. The colour to use is PMS 293C. The percentages of PMS 293C are shown on this page. 55% It is advisable to discuss this background with your local Art Studio. 70% 25% 25% 25% 0% icosapent/doconexent Omacor® Colour Priorities If reproduction considerations, or budgetary constraints, do not allow use of 4-colour reproduction, the colour directions to use are shown below. The PMS colours chosen being those described previously. icosapent/doconexent 3-colour reproduction PMS 2587 PMS 326 PMS 293 icosapent/doconexent 1-colour reproduction PMS 2587 icosapent/doconexent Black and white reproduction icosapent/doconexent For reproduction on a dark background PMS 2587C PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS 326C PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS 293C PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293omitted portions.

88g. docosahexanoic acid [DHA] 1.48g) using on pt outcome, but there was wide warriation in the phospholipid (PL) O3/O6 and EPA/arachidonic acid (AA) levels. The purpose of this study was to determine the cause for this variabilityand to evaluate if the PL O3/O6 and EPA/AA levels affected the outcome of the pts. PLFA levels were measured after 21 months in 23 pts who received O3FA taged 7-10 years and weighing 25-25 kg. and in 11 placebo pts. A Clinical Outcome Score (COS) ranging from -10 to +10 was determined for each pt based on the mean values of estimated GFR and urine protein/creatinnie ratios (UP/C) after 18 and 24 months versus baseline. The dosage of O3FA given to each pt was calculated as g/kg BWt and g/m BSA. Adherence to therapy (Adh-Rx) was based on pill counts. Correlations were determined between the variables of interest and expressed as Xxxxxxxx’x rho (rho). Xxx XX X0/X0 ratios ranged from 0.17 to 0.58 (mean 0.34) and the EPA/AA ratios ranged from 0.06 to 0.91 (0.42 ) in the 23 pts. versus 0.06-0.13 and 0.03-0.09 in the placebo pts. There was no relationship between the O3/O6 and EPA/AA ratios and Adh-RX (rho=0.09, rho=0.20. The PL O3/O6 and EPA/AA ratios were closely correlated with BW (rho=0.68 and 0.80 p=0.0001 and g/m(2) m2 rho=0.69 and 0.82 p=0.0001). As expected the PL EPA/AA and DHA/AA were closely correlated rho=0.85 p=0.0001. The COS correlated with O3/O6 rho=0.53 p=0.009 EPA/AA rho=0.50 p=0.0003 dose in g/kg rho=0.55 p=0.006 and dose/m(2) m2 BSA rho=0.54 p=0.008,. but out Adh-RX (rho=0.21). These data suggest that the efficacy of O3FA Rs for JgAN pts is dose-dependent and that therapy with EPA+DHA is of benefit if dosing is done according to body size and/or EPA/AA levels. Branding Guidelines OMACOR® icosapent/doconexent Table of Contents icosapent/doconexent ® Apo B–100 Apo E Apo C VLDL–Triglycerides VLDL remnant LDL Other sites Liver Inhibition of VLDL– Triglyceride synthesis Branding Omacor® Logotype Symbol Colour Environment Logo Cluster Graphic Styling Branding Omacor® In order to build a pharmaceutical brand in today’s crowded and competitive marketplace, it is essential that all materials maintain a strong, distinctive and consistent visual image. Each of the product’s branding components should therefore be used consistently and repeatedly wherever and whenever the product is promoted in its markets around the world. The benefit to individual marketing companies is that strong product branding produces a more distinct and powerful image for a product. In turn, this complements the other elements of the marketing mix, to build a brand that is stronger, more durable, and therefore more successful. These guidelines are provided to help you to build Omacor® as a pharmaceutical brand that will differentiate itself in the current market and continue to be distinctive and relevant as the market evolves. The four key “global branding” components for Omacor® have been developed to endure over time, regardless of changes in advertising “fashions”. They are[***]: Distinctive Logotype (i.e., the typestyle of the brand name) Unique and Relevant Symbol Distinctive Brand Colour Environment Consistent Visual Styling (typefaces, design, photography and artwork) icosapent/doconexent The Omacor® Logotype + Generic name The representation of the brand name, or ‘logotype’, is the most important of all branding elements. Omacor® is produced by a unique process, making it a unique drug, that therefore deserves a unique and distinctive logotype. icosapent/doconexent The consistent use of the generic name together with the logotype is essential to the pharmaceutical image of Omacor®. The generic name for Omacor® is icosapent/doconexent. The logotype should always be used together with the generic name. It is recommended also to use the symbol wherever possible. The symbol to employ when used with the logotype is the boxed form which can be seen throughout this binder in the logo/symbol configuration. A description of the symbol is given in ‘The Omacor Symbol’ section. Use the Omacor logotype with the ® symbol in all countries where the trademark has been registered, and the ™ symbol in all other countries. The Omacor® Symbol The Omacor® symbol has a blood vessel as its inspiration; it also reflects the ‘O’ of Omacor®. The symbol has been rendered with a ‘segmented’ effect, to allude to the multi-factorial nature of the disease area, and to the multi-stage PUFA-XPC purification process. This segmentation effect also allows the central counterspace to be developed into a heart shape. The Omacor® symbol may be used as a graphic device (as can be seen throughout these guidelines), with the following recommendations: In whole or in part, the surrounding box omitted. In this form it should be noted that the segment which passes through the box appears intact and not divided by the box rule. The individual segments may be used graphically or photographically. The symbol should only be used in the boxed form when in the logo/symbol configuration. The boxed form highlights the symbol. This not only separates the symbol from the logotype as a distinct visual element but creates integrity to the logo/ symbol unit by being the same height as the OMACOR lettering. icosapent/doconexent The Omacor® Logo/Symbol When reproducing the Omacor® logotype and symbol together – the logo/symbol – it is essential that the various elements are kept in the correct proportions and relative positions, together with consistent application of branding colours (see Colour Environment). icosapent/doconexent Colour and black and white reproducible art, for both the larger and smaller versions of the logo/symbol, are included at the back of this binder. The Omacor® Colour Environment It is important that, whenever possible, the Omacor® logotype and symbol be reproduced in full colour. Please see the colour keys Certain information on this page for information required to reproduce these colours has been omitted and filed separately with the Pantone Matching System (PMS) colour system, four-colour process, and Commission. Confidential treatment has been requested with an Apple Macintosh computer. The branding colours selected for Omacor® are: PMS 2587C, PMS 326C, and PMS 293C. When budget considerations require black and white reproduction, please refer respect to the reproducible art sheets at the back of omitted portions. [***]: Certain information on this binder. PMS 2587C Four-colour process C 72% M 79% Y 0% K 0% Apple Macintosh R 54.1% G 12.5% B 85.9% Hue 76.1% Saturation 85.4% Brightness 85.9%. PMS 326C Four-colour process C 94% M 0% Y 43% K 0% Apple Macintosh R 42.0% G 72.5% B 63.1% Hue 44.9% Saturation 42.2% Brightness 72.5% PMS 293C Four-colour process C 100% M 56% Y 0% K 0% Apple Macintosh R 0% G 0% B 70.6% Hue 66.7% Saturation 100% Brightness 70.6% Please note, the colour reproduction in these prints is not exact. icosapent/doconexent The Omacor® Logo Cluster The Omacor® “logo cluster” is created by the combination of the following elements: Eyebrow Logotype Symbol Generic name Biosynthesised icosapent/doconexent These elements are described and discussed on the following page. The Omacor® logo cluster should be used, whenever possible and wherever appropriate, in promotional and educational materials. Reproducible art sheets for the Omacor® logo cluster are included at the back of this binder. Eyebrow The eyebrow sits above the brand name. It may be reproduced in either black or in reversed-out white type. Generic Name The generic name, icosapent/doconexent, is positioned flush left. The recommended size is indicated but, of course, is subject to national regulatory control. It should appear in black, or in reversed-out white type. Biosynthesised icosapent/doconexent The Omacor® Background The Omacor® background page has been developed omitted and filed separately with the Commission. Confidential treatment has been requested with respect to further enhance the page layouts, and to emphasise typographic pointsomitted portions. This background is a series of horizontal bands orchestrated down a blue vignette. 55% As can be seen throughout these guidelines the Omacor® logo cluster should always remain on a white background. 70% It is possible to create this background. The colour to use is PMS 293C. The percentages of PMS 293C are shown [***]: Certain information on this pagepage has been omitted and filed separately with the Commission. 55% It is advisable Confidential treatment has been requested with respect to discuss this background with your local Art Studiothe omitted portions. 70% 25% 25% 25% 0% icosapent/doconexent Omacor® Colour Priorities If reproduction considerations, or budgetary constraints, do not allow use of 4Germany Austria United Kingdom Ireland Belgium Netherlands Luxembourg Switzerland Greece Spain Portugal France Italy X. Xxxxxx Vatican City Norway Sweden Finland Denmark Iceland Estonia Latvia Lithuania Poland Czech Republic Slovakia Hungary Romania Bulgaria Slovenia Croatia Bosnia-colour reproduction, the colour directions to use are shown below. The PMS colours chosen being those described previously. icosapent/doconexent 3-colour reproduction PMS 2587 PMS 326 PMS 293 icosapent/doconexent 1-colour reproduction PMS 2587 icosapent/doconexent Black and white reproduction icosapent/doconexent For reproduction on a dark background PMS 2587C PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS 326C PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS 293C PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293Herzegovina Yugoslavia Macedonia Moldova Albania Malta Cyprus Turkey Israel Belarus Ukraine Russia Georgia Armenia Kazakhstan Azerbaijan Kyrgyzstan Tajikistan Uzbekistan Turkmenistan

88g. docosahexanoic acid [DHA] 1.48g) using on pt outcome, but there was wide warriation in the phospholipid (PL) O3/O6 and EPA/arachidonic acid (AA) levels. The purpose of this study was to determine the cause for this variabilityand to evaluate if the PL O3/O6 and EPA/AA levels affected the outcome of the pts. PLFA levels were measured after 21 months in 23 pts who received O3FA taged 7-10 years and weighing 25-25 kg. and in 11 placebo pts. A Clinical Outcome Score (COS) ranging from -10 to +10 was determined for each pt based on the mean values of estimated GFR and urine protein/creatinnie ratios (UP/C) after 18 and 24 months versus baseline. The dosage of O3FA given to each pt was calculated as g/kg BWt and g/m BSA. Adherence to therapy (Adh-Rx) was based on pill counts. Correlations were determined between the variables of interest and expressed as Xxxxxxxx’x rho (rho). Xxx XX X0/X0 ratios ranged from 0.17 to 0.58 (mean 0.34) and the EPA/AA ratios ranged from 0.06 to 0.91 (0.42 ) in the 23 pts. versus 0.06-0.13 and 0.03-0.09 in the placebo pts. There was no relationship between the O3/O6 and EPA/AA ratios and Adh-RX (rho=0.09, rho=0.20. The PL O3/O6 and EPA/AA ratios were closely correlated with BW (rho=0.68 and 0.80 p=0.0001 and g/m(2) m2 rho=0.69 and 0.82 p=0.0001). As expected the PL EPA/AA and DHA/AA were closely correlated rho=0.85 p=0.0001. The COS correlated with O3/O6 rho=0.53 p=0.009 EPA/AA rho=0.50 p=0.0003 dose in g/kg rho=0.55 p=0.006 and dose/m(2) m2 BSA rho=0.54 p=0.008,. but out Adh-RX (rho=0.21). These data suggest that the efficacy of O3FA Rs for JgAN pts is dose-dependent and that therapy with EPA+DHA is of benefit if dosing is done according to body size and/or EPA/AA levels. Branding Guidelines OMACOR® icosapentSchedule 1.35 Trademarks/doconexent Table of Contents icosapent/doconexent ® Apo B–100 Apo E Apo C VLDL–Triglycerides VLDL remnant LDL Other sites Liver Inhibition of VLDL– Triglyceride synthesis Branding Omacor® Logotype Symbol Colour Environment Logo Cluster Graphic Styling Branding Omacor® In order to build a pharmaceutical brand in today’s crowded and competitive marketplace, it is essential that all materials maintain a strong, distinctive and consistent visual image. Each of the product’s branding components should therefore be used consistently and repeatedly wherever and whenever the product is promoted in its markets around the world. The benefit to individual marketing companies is that strong product branding produces a more distinct and powerful image for a product. In turn, this complements the other elements of the marketing mix, to build a brand that is stronger, more durable, and therefore more successful. These guidelines are provided to help you to build Omacor® as a pharmaceutical brand that will differentiate itself in the current market and continue to be distinctive and relevant as the market evolves. The four key “global branding” components for Omacor® have been developed to endure over time, regardless of changes in advertising “fashions”. They areTrademark Specifications (Attached) Schedule 2.6 [***] [***]: Distinctive Logotype (i.e., the typestyle of the brand name) Unique and Relevant Symbol Distinctive Brand Colour Environment Consistent Visual Styling (typefaces, design, photography and artwork) icosapent/doconexent The Omacor® Logotype + Generic name The representation of the brand name, or ‘logotype’, is the most important of all branding elements. Omacor® is produced by a unique process, making it a unique drug, that therefore deserves a unique and distinctive logotype. icosapent/doconexent The consistent use of the generic name together with the logotype is essential to the pharmaceutical image of Omacor®. The generic name for Omacor® is icosapent/doconexent. The logotype should always be used together with the generic name. It is recommended also to use the symbol wherever possible. The symbol to employ when used with the logotype is the boxed form which can be seen throughout this binder in the logo/symbol configuration. A description of the symbol is given in ‘The Omacor Symbol’ section. Use the Omacor logotype with the ® symbol in all countries where the trademark has been registered, and the ™ symbol in all other countries. The Omacor® Symbol The Omacor® symbol has a blood vessel as its inspiration; it also reflects the ‘O’ of Omacor®. The symbol has been rendered with a ‘segmented’ effect, to allude to the multi-factorial nature of the disease area, and to the multi-stage PUFA-XPC purification process. This segmentation effect also allows the central counterspace to be developed into a heart shape. The Omacor® symbol may be used as a graphic device (as can be seen throughout these guidelines), with the following recommendations: In whole or in part, the surrounding box omitted. In this form it should be noted that the segment which passes through the box appears intact and not divided by the box rule. The individual segments may be used graphically or photographically. The symbol should only be used in the boxed form when in the logo/symbol configuration. The boxed form highlights the symbol. This not only separates the symbol from the logotype as a distinct visual element but creates integrity to the logo/ symbol unit by being the same height as the OMACOR lettering. icosapent/doconexent The Omacor® Logo/Symbol When reproducing the Omacor® logotype and symbol together – the logo/symbol – it is essential that the various elements are kept in the correct proportions and relative positions, together with consistent application of branding colours (see Colour Environment). icosapent/doconexent Colour and black and white reproducible art, for both the larger and smaller versions of the logo/symbol, are included at the back of this binder. The Omacor® Colour Environment It is important that, whenever possible, the Omacor® logotype and symbol be reproduced in full colour. Please see the colour keys Certain information on this page for information required to reproduce these colours has been omitted and filed separately with the Pantone Matching System (PMS) colour system, four-colour process, and Commission. Confidential treatment has been requested with an Apple Macintosh computer. The branding colours selected for Omacor® are: PMS 2587C, PMS 326C, and PMS 293C. When budget considerations require black and white reproduction, please refer respect to the reproducible art sheets at the back of omitted portions. Schedule 3.6 PRONOVA Rights to Clinical Data - Clinical trials with OMACOR® [***] [***]: Certain information on this binder. PMS 2587C Four-colour process C 72% M 79% Y 0% K 0% Apple Macintosh R 54.1% G 12.5% B 85.9% Hue 76.1% Saturation 85.4% Brightness 85.9%. PMS 326C Four-colour process C 94% M 0% Y 43% K 0% Apple Macintosh R 42.0% G 72.5% B 63.1% Hue 44.9% Saturation 42.2% Brightness 72.5% PMS 293C Four-colour process C 100% M 56% Y 0% K 0% Apple Macintosh R 0% G 0% B 70.6% Hue 66.7% Saturation 100% Brightness 70.6% Please note, the colour reproduction in these prints is not exact. icosapent/doconexent The Omacor® Logo Cluster The Omacor® “logo cluster” is created by the combination of the following elements: Eyebrow Logotype Symbol Generic name Biosynthesised icosapent/doconexent These elements are described and discussed on the following page. The Omacor® logo cluster should be used, whenever possible and wherever appropriate, in promotional and educational materials. Reproducible art sheets for the Omacor® logo cluster are included at the back of this binder. Eyebrow The eyebrow sits above the brand name. It may be reproduced in either black or in reversed-out white type. Generic Name The generic name, icosapent/doconexent, is positioned flush left. The recommended size is indicated but, of course, is subject to national regulatory control. It should appear in black, or in reversed-out white type. Biosynthesised icosapent/doconexent The Omacor® Background The Omacor® background page has been developed omitted and filed separately with the Commission. Confidential treatment has been requested with respect to further enhance the page layouts, and to emphasise typographic pointsomitted portions. This background is a series of horizontal bands orchestrated down a blue vignette. 55% As can be seen throughout these guidelines the Omacor® logo cluster should always remain on a white background. 70% It is possible to create this background. The colour to use is PMS 293C. The percentages of PMS 293C are shown Schedule 4.1 Payment Models [***] [***]: Certain information on this pagepage has been omitted and filed separately with the Commission. 55% It is advisable Confidential treatment has been requested with respect to discuss this background with your local Art Studiothe omitted portions. 70% 25% 25% 25% 0% icosapent/doconexent Omacor® Colour Priorities If reproduction considerationsSchedule 5.2 Forecasting, Ordering and Delivery procedures (examples) Schedule 5.12(b) Territories in which PRONOVA Currently has Licensing or budgetary constraints, do not allow use of 4Supply Agreements for API (or Active Pharmaceutical Ingredients Similar to API) Europe & “former Soviet Union” Germany Austria United Kingdom Ireland Belgium Netherlands Luxembourg Switzerland Greece Spain Portugal France Italy X. Xxxxxx Vatican City Norway Sweden Finland Denmark Iceland Estonia Latvia Lithuania Poland Czech Republic Slovakia Hungary Romania Bulgaria Slovenia Croatia Bosnia-colour reproduction, the colour directions to use are shown below. The PMS colours chosen being those described previously. icosapent/doconexent 3Herzegovina Yugoslavia Macedonia Moldova Albania Malta Cyprus Turkey Israel Belarus Ukraine Russia Georgia Armenia Kazakhstan Azerbaijan Kyrgyzstan Tajikistan Uzbekistan Turkmenistan Middle East Jordan Lebanon Syria Saudi-colour reproduction PMS 2587 PMS 326 PMS 293 icosapent/doconexent 1Arabia Yemen Oman United Arab Emirates Qatar Bahrain Kuwait Asia Thailand Myanmar Malaysia Philippines Singapore Vietnam Indonesia Brunei Sri Lanka Laos Cambodia South Korea Taiwan Australia North America Canada Africa Algeria Morocco Tunisia Benin Burkina Burundi Camerun Congo Ivory Coast Guinea Madagaskar Mali Mauritania Niger Central African Republic Djibouti Rwanda Senegal Tchad Togo Congo (former Zaire) South-colour reproduction PMS 2587 icosapent/doconexent Black and white reproduction icosapent/doconexent For reproduction on a dark background PMS 2587C PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS2587 PMS 326C PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS326 PMS 293C PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293 PMS293Africa Central & South America Argentina Bolivia Brazil Chile Colombia Costa Rica Dominican Republic Equador El Salvador Guatemala Honduras Mexico Nicaragua Panama Paraguay Peru Uruguay Venezuela Schedule 7.2 Combination Product Royalty Rates